The Intelligent Diabetes TelemonitoRing Using Decision Support to Treat Patients on Insulin Therapy
The trial is an open-label, randomized controlled trial. Patients with T2D on insulin therapy will be randomized to an intelligent telemonitoring group (intervention), a telemonitoring group (control), and a usual care group (control). Both the intelligent telemonitoring group and the telemonitoring group will use various devices at home. Hospital staff will monitor their data for three months. In the intelligent telemonitoring group, hospital staff and participants will be supported by decision-support algorithms…
Conditions studied
Type 2 Diabetes Treated With Insulin
About this study
The trial is an open-label, randomized controlled trial. Patients with T2D on insulin therapy will be randomized to an intelligent telemonitoring group (intervention), a telemonitoring group (control), and a usual care group (control). Both the intelligent telemonitoring group and the telemonitoring group will use various devices at home. Hospital staff will monitor their data for three months. In the intelligent telemonitoring group, hospital staff and participants will be supported by decision-support algorithms in the management of insulin treatment.
Interventions
- Device: Intelligent telemonitoring — Telemonitoring using CGM, insulin pen data, and Fitbit data supported by data-driven decision support.
- Device: Telemonitoring — Telemonitoring using CGM, insulin pen data, and Fitbit data
Primary outcomes
- CGM time in range (At baseline to three months after randomization)
Eligibility information
Study locations
- Department of Endocrinology, Aalborg, North Jutland 9000 Denmark
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.